| NCT04244591 |
Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure |
https://ClinicalTrials.gov/show/NCT04244591 |
| NCT04252118 |
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus |
https://ClinicalTrials.gov/show/NCT04252118 |
| NCT04251871 |
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection |
https://ClinicalTrials.gov/show/NCT04251871 |
| NCT04252274 |
Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV |
https://ClinicalTrials.gov/show/NCT04252274 |
| NCT04252885 |
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection |
https://ClinicalTrials.gov/show/NCT04252885 |
| NCT04251767 |
Washed Microbiota Transplantation for Patients With 2019-nCoV Infection |
https://ClinicalTrials.gov/show/NCT04251767 |
| NCT04257656 |
Severe 2019-nCoV Remdesivir RCT |
https://ClinicalTrials.gov/show/NCT04257656 |
| NCT04252664 |
Mild/Moderate 2019-nCoV Remdesivir RCT |
https://ClinicalTrials.gov/show/NCT04252664 |
| NCT04263402 |
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia |
https://ClinicalTrials.gov/show/NCT04263402 |
| NCT04255017 |
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia |
https://ClinicalTrials.gov/show/NCT04255017 |
| NCT04254874 |
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia |
https://ClinicalTrials.gov/show/NCT04254874 |
| NCT04264533 |
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia |
https://ClinicalTrials.gov/show/NCT04264533 |
| NCT04261270 |
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia |
https://ClinicalTrials.gov/show/NCT04261270 |
| NCT04261517 |
Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) |
https://ClinicalTrials.gov/show/NCT04261517 |
| NCT04261907 |
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection |
https://ClinicalTrials.gov/show/NCT04261907 |
| NCT04260594 |
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus |
https://ClinicalTrials.gov/show/NCT04260594 |
| NCT04275245 |
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia |
https://ClinicalTrials.gov/show/NCT04275245 |
| NCT04269525 |
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia |
https://ClinicalTrials.gov/show/NCT04269525 |
| NCT04268537 |
Immunoregulatory Therapy for 2019-nCoV |
https://ClinicalTrials.gov/show/NCT04268537 |
| NCT04264858 |
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients |
https://ClinicalTrials.gov/show/NCT04264858 |
| NCT04282902 |
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection |
https://ClinicalTrials.gov/show/NCT04282902 |
| NCT04276688 |
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment |
https://ClinicalTrials.gov/show/NCT04276688 |
| NCT04280224 |
NK Cells Treatment for Novel Coronavirus Pneumonia |
https://ClinicalTrials.gov/show/NCT04280224 |
| NCT04275414 |
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia |
https://ClinicalTrials.gov/show/NCT04275414 |
| NCT04273646 |
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia |
https://ClinicalTrials.gov/show/NCT04273646 |
| NCT04273581 |
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 |
https://ClinicalTrials.gov/show/NCT04273581 |
| NCT04273529 |
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia |
https://ClinicalTrials.gov/show/NCT04273529 |
| NCT04304313 |
A Pilot Study of Sildenafil in COVID-19 |
https://ClinicalTrials.gov/show/NCT04304313 |
| NCT04273763 |
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) |
https://ClinicalTrials.gov/show/NCT04273763 |
| NCT04293887 |
Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients |
https://ClinicalTrials.gov/show/NCT04293887 |
| NCT04273321 |
Efficacy and Safety of Corticosteroids in COVID-19 |
https://ClinicalTrials.gov/show/NCT04273321 |
| NCT04279197 |
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu |
https://ClinicalTrials.gov/show/NCT04279197 |
| NCT04276987 |
A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia |
https://ClinicalTrials.gov/show/NCT04276987 |
| NCT04275388 |
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia |
https://ClinicalTrials.gov/show/NCT04275388 |
| NCT04276896 |
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine |
https://ClinicalTrials.gov/show/NCT04276896 |
| NCT04278963 |
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 |
https://ClinicalTrials.gov/show/NCT04278963 |
| NCT04285190 |
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 |
https://ClinicalTrials.gov/show/NCT04285190 |
| NCT04281693 |
A New Screening Strategy for 2019 Novel Coronavirus Infection |
https://ClinicalTrials.gov/show/NCT04281693 |
| NCT04280588 |
Fingolimod in COVID-19 |
https://ClinicalTrials.gov/show/NCT04280588 |
| NCT04280705 |
Adaptive COVID-19 Treatment Trial |
https://ClinicalTrials.gov/show/NCT04280705 |
| NCT04287686 |
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
https://ClinicalTrials.gov/show/NCT04287686 |
| NCT04283461 |
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection |
https://ClinicalTrials.gov/show/NCT04283461 |
| NCT04283838 |
Humanistic Care in Healthcare Workers in Coronavirus Disease 2019 |
https://ClinicalTrials.gov/show/NCT04283838 |
| NCT04283825 |
Humanistic Care in Patients With Coronavirus Disease 2019 |
https://ClinicalTrials.gov/show/NCT04283825 |
| NCT04303299 |
Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial |
https://ClinicalTrials.gov/show/NCT04303299 |
| NCT04293692 |
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus |
https://ClinicalTrials.gov/show/NCT04293692 |
| NCT04288102 |
Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) |
https://ClinicalTrials.gov/show/NCT04288102 |
| NCT04286503 |
The Clinical Study of Carrimycin on Treatment Patients With COVID-19 |
https://ClinicalTrials.gov/show/NCT04286503 |
| NCT04291729 |
Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection |
https://ClinicalTrials.gov/show/NCT04291729 |
| NCT04290871 |
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. |
https://ClinicalTrials.gov/show/NCT04290871 |
| NCT04302519 |
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells |
https://ClinicalTrials.gov/show/NCT04302519 |
| NCT04290858 |
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection |
https://ClinicalTrials.gov/show/NCT04290858 |
| NCT04291053 |
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 |
https://ClinicalTrials.gov/show/NCT04291053 |
| NCT04299152 |
Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 |
https://ClinicalTrials.gov/show/NCT04299152 |
| NCT04292899 |
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19) |
https://ClinicalTrials.gov/show/NCT04292899 |
| NCT04292730 |
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment |
https://ClinicalTrials.gov/show/NCT04292730 |
| NCT04295551 |
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) |
https://ClinicalTrials.gov/show/NCT04295551 |
| NCT04296643 |
Medical Masks vs N95 Respirators for COVID-19 |
https://ClinicalTrials.gov/show/NCT04296643 |
| NCT04308317 |
Tetrandrine Tablets Used in the Treatment of COVID-19 |
https://ClinicalTrials.gov/show/NCT04308317 |
| NCT04299724 |
Safety and Immunity of Covid-19 aAPC Vaccine |
https://ClinicalTrials.gov/show/NCT04299724 |
| NCT04304053 |
Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic |
https://ClinicalTrials.gov/show/NCT04304053 |
| NCT04303507 |
Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting |
https://ClinicalTrials.gov/show/NCT04303507 |
| NCT04306055 |
Blood Donor Recruitment During Epidemic of COVID-19 |
https://ClinicalTrials.gov/show/NCT04306055 |
| NCT04305106 |
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT |
https://ClinicalTrials.gov/show/NCT04305106 |
| NCT04305457 |
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 |
https://ClinicalTrials.gov/show/NCT04305457 |
| NCT04304690 |
Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic |
https://ClinicalTrials.gov/show/NCT04304690 |
| NCT04307693 |
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) |
https://ClinicalTrials.gov/show/NCT04307693 |
| NCT04306393 |
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 |
https://ClinicalTrials.gov/show/NCT04306393 |
| NCT04308668 |
Post-exposure Prophylaxis for SARS-Coronavirus-2 |
https://ClinicalTrials.gov/show/NCT04308668 |
| NCT04316377 |
Norwegian Coronavirus Disease 2019 Study |
https://ClinicalTrials.gov/show/NCT04316377 |
| NCT04315948 |
Trial of Treatments for COVID-19 in Hospitalized Adults |
https://ClinicalTrials.gov/show/NCT04315948 |
| NCT04312009 |
Losartan for Patients With COVID-19 Requiring Hospitalization |
https://ClinicalTrials.gov/show/NCT04312009 |
| NCT04311177 |
Losartan for Patients With COVID-19 Not Requiring Hospitalization |
https://ClinicalTrials.gov/show/NCT04311177 |
| NCT04316728 |
Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19 |
https://ClinicalTrials.gov/show/NCT04316728 |
| NCT04315480 |
Tocilizumab for SARS-CoV2 Severe Pneumonitis |
https://ClinicalTrials.gov/show/NCT04315480 |
| NCT04311697 |
Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress |
https://ClinicalTrials.gov/show/NCT04311697 |
| NCT04315298 |
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 |
https://ClinicalTrials.gov/show/NCT04315298 |
| NCT04313322 |
Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells |
https://ClinicalTrials.gov/show/NCT04313322 |
| NCT04313127 |
Phase I Clinical Trial in Healthy Adult |
https://ClinicalTrials.gov/show/NCT04313127 |
| NCT04312243 |
NO Prevention of COVID-19 for Healthcare Providers |
https://ClinicalTrials.gov/show/NCT04312243 |
| NCT04310865 |
Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 |
https://ClinicalTrials.gov/show/NCT04310865 |
| NCT04313023 |
The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2 |
https://ClinicalTrials.gov/show/NCT04313023 |
| NCT04312997 |
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection |
https://ClinicalTrials.gov/show/NCT04312997 |
| NCT04315987 |
NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia |
https://ClinicalTrials.gov/show/NCT04315987 |
| NCT04315896 |
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) |
https://ClinicalTrials.gov/show/NCT04315896 |
| NCT04318015 |
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) |
https://ClinicalTrials.gov/show/NCT04318015 |
| NCT04317092 |
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) |
https://ClinicalTrials.gov/show/NCT04317092 |
| NCT04317040 |
CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment |
https://ClinicalTrials.gov/show/NCT04317040 |